Technical analysis of Erasca, Inc. (ERAS): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway.
Price Performance
| 1 month | -2.65% |
| 3 months | -19.56% |
| Year-to-date | +285.75% |
| 1 year | +492.98% |
| 3 years | +510.64% |
| 5 years | -27.12% |
52-Week Range
| 52-week High | $24.28 |
| 52-week Low | $2.11 |
| Avg Volume (90d) | 4.7M |
Technical Indicators
| SMA 50 | $15.48 |
| SMA 200 | $15.00 |
| Beta | 1.05 |
| 30-day Volatility (annualised) | 66.3% |
| Price vs SMA 50 | -7.3% |
| Price vs SMA 200 | -4.3% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-12 | $3.72 | |
| 2026-01 | $10.51 | +182.5% |
| 2026-02 | $13.66 | +30.0% |
| 2026-03 | $16.18 | +18.4% |
| 2026-04 | $10.65 | -34.2% |
| 2026-05 | $12.84 | +20.6% |
| 2026-06 | $18.32 | +42.7% |
| 2026-07 | $18.15 | -0.9% |
| 2026-08 | $17.88 | -1.5% |
| 2026-09 | $14.66 | -18.0% |
| 2026-10 | $14.35 | -2.1% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-11-11 | $-0.13 | |
| 2026-08-12 | $-0.11 | |
| 2026-05-11 | $-0.11 | |
| 2026-03-12 | $-0.11 | |
| 2025-11-12 | $-0.11 | |
| 2025-08-12 | $-0.12 | |
| 2025-05-13 | $-0.12 | |
Price
| Price | $14.35 (closing price, October 30, 2026) |
| Market Cap | $5.0B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 12.35 |
| EV / EBITDA | -17.66 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.12 |
| Current Ratio | 8.29 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 5.45 |